Physician profile
Atul Syal
NPI 1831160183
$18,901.06
in general payments reported to CMS, 2019-2025
76 companies · $4,120 in 2025
The $4,120 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,288 · 2020: $1,147 · 2021: $1,823 · 2022: $3,517 · 2023: $3,412 · 2024: $3,595 · 2025: $4,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $8.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,118.45 |
| Education | $8.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,486.67 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Sk Life Science, INC. | $1,487.13 | 2020-2025 | |
| Abbvie INC. | $1,224.98 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Biogen, INC. | $942.79 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Teva Pharmaceuticals USA, INC. | $841.07 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Eisai INC. | $818.48 | 2019-2025 | |
| Lilly USA, LLC | $810.07 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Alexion Pharmaceuticals, INC. | $743.44 | 2019-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $732.02 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $489.76 | 2019-2025 | Nuplazid |
| Argenx US, INC. | $488.25 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Abbott Laboratories | $479.60 | 2019-2025 | Octrode, Infinity, Proclaim |
| Celgene Corporation | $455.87 | 2022-2025 | Zeposia |
| Supernus Pharmaceuticals, INC. | $447.36 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $440.35 | 2019-2025 | Crexont, Rytary |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atul Syal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.